<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39406462</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-2044</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>21</Day></PubDate></JournalIssue><Title>Archives of disease in childhood</Title><ISOAbbreviation>Arch Dis Child</ISOAbbreviation></Journal><ArticleTitle>COVID-19 vaccine effectiveness and uptake in a national cohort of English children and young people with life-limiting neurodisability.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">archdischild-2024-327293</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/archdischild-2024-327293</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To investigate SARS-CoV-2 vaccine uptake and effectiveness in children and young people (CYP) with life-limiting neurodisability.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">We undertook a retrospective cohort study using national hospital data in England from 21 December 2020 to 2 September 2022 to describe SARS-CoV-2 vaccination uptake, and then examined COVID-19 hospitalisation, paediatric intensive care unit (PICU) admission and death following SARS-CoV-2 infection by vaccination status using Cox regression models.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">CYP aged 5-17 with life-limiting neurodisability.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We identified 38 067 CYP with life-limiting neurodisability; 13 311 (35.0%) received at least one SARS-CoV-2 vaccine, with uptake higher among older, white CYP, from less deprived neighbourhoods. Of 8134 CYP followed up after a positive SARS-CoV-2 test, 1547 (19%) were vaccinated. Within 28 days of infection, 309 (4.7%) unvaccinated CYP were hospitalised with COVID-19 compared with 75 (4.8%) vaccinated CYP. 46 (0.7%) unvaccinated CYP were admitted to PICU compared with 10 (0.6%) vaccinated CYP. 20 CYP died within 28 days of SARS-CoV-2 infection, of which 13 were unvaccinated. Overall, adjusted hazard of hospitalisation for COVID-19 or admission to PICU did not vary by vaccination status. When the Alpha-Delta SARS-CoV-2 variants were dominant, hazard of hospitalisation with COVID-19 was significantly lower among vaccinated CYP (HR 0.26 (0.09 to 0.74)), with no difference seen during Omicron (HR 1.16 (0.74 to 1.81)).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">SARS-CoV-2 vaccination was protective of COVID-19 hospitalisation among CYP with life-limiting neurodisability during Alpha-Delta, but not for other SARS-CoV-2 variants. Vaccine uptake was low and varied by ethnicity and deprivation.</AbstractText><CopyrightInformation>© Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cruz</LastName><ForeName>Joana</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-5431-0520</Identifier><AffiliationInfo><Affiliation>Population, Policy &amp; Practice Research Programme, UCL GOS Institute of Child Health, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harwood</LastName><ForeName>Rachel</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-3440-3142</Identifier><AffiliationInfo><Affiliation>Paediatric Surgery, Alder Hey Children's NHS Foundation Trust, Liverpool, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kenny</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Paediatric Surgery, Alder Hey Children's NHS Foundation Trust, Liverpool, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NHS England and NHS Improvement London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clark</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>NHS England and NHS Improvement London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>Peter J</ForeName><Initials>PJ</Initials><Identifier Source="ORCID">0000-0003-0669-2485</Identifier><AffiliationInfo><Affiliation>Bristol Royal Hospital for Children, Bristol, Select State, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Draper</LastName><ForeName>Elizabeth S</ForeName><Initials>ES</Initials><Identifier Source="ORCID">0000-0001-9340-8176</Identifier><AffiliationInfo><Affiliation>Paediatric Intensive Care Audit Network, Department of Population Health Sciences, University of Leicester, Leicester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hargreaves</LastName><ForeName>Dougal</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Mohn Centre for Children's Health and Wellbeing, Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ladhani</LastName><ForeName>Shamez N</ForeName><Initials>SN</Initials><Identifier Source="ORCID">0000-0002-0856-2476</Identifier><AffiliationInfo><Affiliation>Immunisation Department, UK Health Security Agency, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Neonatal and Paediatric Infection (CNPI), Immunisation Department, St George's University of London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luyt</LastName><ForeName>Karen</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-9806-1092</Identifier><AffiliationInfo><Affiliation>Bristol Medical School, University of Bristol, Bristol, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turner</LastName><ForeName>Stephen W</ForeName><Initials>SW</Initials><Identifier Source="ORCID">0000-0001-8393-5060</Identifier><AffiliationInfo><Affiliation>NHS Grampian, Aberdeen, Aberdeen, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Whittaker</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-7944-8793</Identifier><AffiliationInfo><Affiliation>Paediatric Infectious Diseases, Imperial College Healthcare NHS Trust, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Section of Paediatric Infectious Diseases, Faculty of Medicine, Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hardelid</LastName><ForeName>Pia</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-0154-1306</Identifier><AffiliationInfo><Affiliation>Population, Policy &amp; Practice Research Programme, UCL GOS Institute of Child Health, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fraser</LastName><ForeName>Lorna K</ForeName><Initials>LK</Initials><Identifier Source="ORCID">0000-0002-1360-4191</Identifier><AffiliationInfo><Affiliation>Cicely Saunders Institute, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Viner</LastName><ForeName>Russell M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Population, Policy &amp; Practice Research Programme, UCL GOS Institute of Child Health, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ward</LastName><ForeName>Joseph Lloyd</ForeName><Initials>JL</Initials><Identifier Source="ORCID">0000-0001-7263-8845</Identifier><AffiliationInfo><Affiliation>Population, Policy &amp; Practice Research Programme, UCL GOS Institute of Child Health, London, UK joseph.ward@ucl.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Arch Dis Child</MedlineTA><NlmUniqueID>0372434</NlmUniqueID><ISSNLinking>0003-9888</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Covid-19</Keyword><Keyword MajorTopicYN="N">Epidemiology</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>4</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>4</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>15</Day><Hour>20</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39406462</ArticleId><ArticleId IdType="doi">10.1136/archdischild-2024-327293</ArticleId><ArticleId IdType="pii">archdischild-2024-327293</ArticleId></ArticleIdList></PubmedData></PubmedArticle>